查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1980188

抗凝血剂市场规模、份额、成长及全球产业分析：按类型、应用和地区划分，并提供 2026-2034 年的洞察和预测

Anticoagulants Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 149 Pages | 商品交期: 请询问到货日

价格

抗凝血剂市场的成长要素

2025年全球抗凝血剂市场规模为414.1亿美元。预计该市场将从2026年的455.1亿美元成长至2034年的970.9亿美元，在预测期间（2026-2034年）复合年增长率高达9.93%。北美地区在2025年占据全球市场主导地位，市占率达50.70%，主要得益于该地区心血管疾病的高发生率和强大的产品创新能力。

抗凝血剂，俗称“血液稀释剂”，透过抑制血栓形成，在心血管疾病（CVD）的预防和治疗中发挥至关重要的作用。随着心肌梗塞、肺动脉栓塞和深层静脉栓塞症等心血管疾病在全球的增加，对先进抗凝血疗法的需求持续增长。

市场驱动因素

心血管疾病盛行率不断上升

心血管疾病仍是全球主要死因之一。全球健康评估显示，大多数心血管疾病相关死亡是由心肌梗塞和中风引起的。抗凝血剂在治疗这些疾病中至关重要，它能预防血栓形成并减少併发症。人们对心臟健康和预防保健意识的不断提高，正显着推动市场成长。

新型口服抗凝血剂（NOACs）的创新

新型口服抗凝血药物（NOACs），例如Apixaban和Rivaroxaban的问世，彻底改变了治疗方法。与传统治疗方法相比，这些先进药物具有更高的安全性和便利性。旗舰产品如艾乐妥和拜瑞妥的强劲销售业绩持续推动着整体市场收入的成长。

市场区隔分析

疾病特异性

市场细分将这些​​疾病分为肺动脉栓塞（PE）、深层静脉栓塞症（DVT）、心房颤动（AF）、心肌梗塞和其他疾病。

预计到2026年，肺动脉栓塞（PE）领域将主导市场，占76.34%的市占率。 2025年，该领域创造了315.3亿美元的收入，反映出治疗需求强劲。肥胖症发生率上升、癌症盛行率增加以及久坐不动的生活方式是肺栓塞发病率上升的主要驱动因素。

由于诊断率的提高和长期治疗需求的增加，深层静脉栓塞症（DVT）和心房颤动（AF）的细分市场也呈现稳定成长。心肌梗塞细分市场仍然十分重要，因为抗凝血剂对于二级预防至关重要。

透过行政途径

根据给药途径，市场分为口服製剂和注射製剂。

预计到2026年，口服抗凝血剂将以85.58%的市场份额引领市场，这主要得益于患者用药的便利性、强大的产品平臺以及新型口服抗凝血剂（NOAC）的日益普及。注射用抗凝血剂，包括Warfarin和肝素类药物，在医院环境中仍保持稳定的需求，但面临口服药物的竞争。

透过分销管道

市场分为医院药局、零售药局、网路药局和其他药局。

由于抗凝血药物需要谨慎处方和监测，预计到2026年，医院药局将占据46.04%的市场份额。零售药房将紧随其后，因为处方笺续药更加便捷。同时，由于数位化的进步，预计线上药局将呈现最高的成长率。

区域趋势

北美洲

预计北美市场规模将在2025年达到209.8亿美元，并在2026年成长至233亿美元。该地区预计将在整个预测期内保持其主导地位。光是美国市场预计在2026年就将达到217.4亿美元。心血管疾病的高发生率、高肥胖率以及强大的研发投入是推动该地区成长的主要因素。

欧洲

预计欧洲市场在预测期内将以7.6%的复合年增长率成长。英国市场预计到2026年将达到20.5亿美元，而德国同年将达到32.5亿美元。心血管疾病死亡率的上升支撑了市场需求。

亚太地区

亚太地区预计将呈现最高的成长率。日本市场规模预计2025年达到32.1亿美元，2026年达到35.6亿美元。中国市场预估2026年达到25.6亿美元，复合年增长率高达13.40%。医疗保健支出不断增长和健康意识的提高是成长要素。

在拉丁美洲、中东和非洲地区，由于医疗基础设施的改善和疾病流行率的上升，预计将稳定成长。

目录

第一章：引言

第二章执行摘要

第三章 市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机会

第四章：主要考虑因素

  • 主要心血管疾病盛行率：依主要国家划分
  • 新型口服抗凝血剂（NOACs）概述
  • 管道分析
  • 产业主要趋势：併购等。
  • 新产品发布
  • 主要国家的监管状况
  • 兑换状态：依主要国家划分

第五章：2021-2034年全球抗凝血剂市场分析、洞察与预测

  • 主要发现与总结
  • 市场分析、洞察与预测：按适用疾病分类。
    • 肺动脉栓塞（PE）
    • 深层静脉栓塞症（DVT）
    • 心房颤动
    • 心肌梗塞
    • 其他的
  • 市场分析、洞察与预测：按给药途径
    • 口服
    • 注射药物
  • 市场分析、洞察与预测：按分销管道划分
    • 医院和药房
    • 零售药房
    • 网路药房
    • 其他的
  • 市场分析、洞察与预测：按国家/地区划分
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章：北美抗凝血剂市场分析、洞察与预测（2021-2034年）

  • 国家
    • 我们
    • 加拿大

第七章：欧洲抗凝血剂市场分析、洞察与预测（2021-2034年）

  • 国家
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪地那维亚
    • 其他欧洲国家

第八章：亚太地区抗凝血剂市场分析、洞察与预测（2021-2034年）

  • 国家
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 东南亚
    • 其他亚太国家

第九章：拉丁美洲抗凝血剂市场分析、洞察与预测（2021-2034年）

  • 国家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲国家

第十章：中东和非洲抗凝血剂市场分析、洞察与预测（2021-2034年）

  • 国家
    • 海湾合作委员会国家
    • 南非
    • 其他中东和非洲国家

第十一章 竞争分析

  • 主要行业趋势
  • 全球市占率分析（2025 年）
  • 竞争对手仪錶板
  • 主要企业比较分析
    • 百时美施贵宝
    • 辉瑞
    • 拜耳股份公司
    • 强生製药
    • Eisai
    • 其他主要企业

第十二章 战略建议

Product Code: FBI101807

Growth Factors of anticoagulants Market

The global anticoagulants market size was valued at USD 41.41 billion in 2025. The market is projected to grow from USD 45.51 billion in 2026 to USD 97.09 billion by 2034, exhibiting a strong CAGR of 9.93% during the forecast period (2026-2034). North America dominated the global market with a 50.70% share in 2025, driven by the high prevalence of cardiovascular diseases and strong product innovation.

Anticoagulants, commonly known as blood thinners, play a critical role in preventing and treating cardiovascular diseases (CVDs) by reducing the formation of blood clots. With cardiovascular disorders such as heart attacks, strokes, pulmonary embolism, and deep vein thrombosis rising globally, demand for advanced anticoagulant therapies continues to grow.

Market Drivers

Rising Prevalence of Cardiovascular Diseases

Cardiovascular diseases remain one of the leading causes of mortality worldwide. According to global health estimates, a large percentage of deaths related to CVD are caused by heart attacks and strokes. Anticoagulants are essential in managing these conditions by preventing clot formation and reducing complications. Increasing awareness about heart health and preventive treatment significantly supports market expansion.

Innovation in Novel Oral Anticoagulants (NOACs)

The introduction of novel oral anticoagulants (NOACs), such as apixaban and rivaroxaban, has transformed treatment approaches. These advanced drugs offer improved safety profiles and convenience compared to traditional therapies. Strong sales performance of leading products like Eliquis and Xarelto continues to fuel overall market revenue growth.

Market Segmentation Analysis

By Disease Indication

The market is segmented into pulmonary embolism (PE), deep vein thrombosis (DVT), atrial fibrillation (AF), heart attacks, and others.

The pulmonary embolism (PE) segment is expected to dominate, holding a 76.34% share in 2026. In 2025, this segment generated USD 31.53 billion in revenue, reflecting high treatment demand. Rising obesity, cancer prevalence, and sedentary lifestyles are key contributors to PE incidence.

The DVT and atrial fibrillation segments also show strong growth due to increasing diagnosis rates and long-term therapy requirements. The heart attack segment remains significant, as anticoagulants are essential in secondary prevention.

By Route of Administration

Based on administration route, the market is divided into oral and injectable.

The oral segment is projected to lead with an 85.58% share in 2026, owing to patient convenience, strong product pipeline, and higher adoption of NOACs. Injectable anticoagulants, including warfarin and heparin-based drugs, maintain steady demand in hospital settings but face competition from oral alternatives.

By Distribution Channel

The market is categorized into hospital pharmacies, retail pharmacies, online pharmacies, and others.

The hospital pharmacies segment is expected to hold a 46.04% share in 2026, as anticoagulants require careful prescription and monitoring. Retail pharmacies follow closely due to refill convenience, while online pharmacies are projected to witness the fastest growth rate due to increasing digital adoption.

Regional Insights

North America

North America accounted for USD 20.98 billion in 2025 and grew to USD 23.3 billion in 2026. The region is expected to maintain dominance throughout the forecast period. The U.S. market alone was valued at USD 21.74 billion in 2026. High cardiovascular disease prevalence, obesity rates, and strong R&D initiatives drive regional growth.

Europe

Europe is anticipated to grow at a CAGR of 7.6% during the forecast period. The UK market reached USD 2.05 billion in 2026, while Germany accounted for USD 3.25 billion in 2026. Rising mortality from cardiovascular disorders supports market demand.

Asia Pacific

Asia Pacific is expected to witness the highest growth rate. Japan's market reached USD 3.21 billion in 2025 and USD 3.56 billion in 2026. China recorded USD 2.56 billion in 2026 and is projected to grow at a strong CAGR of 13.40%. Increasing healthcare expenditure and awareness are major growth factors.

Latin America and the Middle East & Africa are projected to experience steady growth due to improving healthcare infrastructure and rising disease prevalence.

Competitive Landscape

Leading players in the anticoagulants market include Bristol-Myers Squibb Company, Pfizer Inc., Bayer AG, Janssen Pharmaceuticals, Inc., and Eisai Co., Ltd. These companies dominate through strong product portfolios, strategic acquisitions, and continuous R&D investments. However, increasing generic competition may moderate pricing power in certain regions.

Conclusion

The global anticoagulants market demonstrates strong and sustained growth, rising from USD 41.41 billion in 2025 to a projected USD 97.09 billion by 2034, supported by a CAGR of 9.93%. Increasing cardiovascular disease prevalence, growing awareness, and innovation in novel oral anticoagulants are key growth drivers. While North America leads in revenue share, Asia Pacific is emerging as the fastest-growing region. Continuous R&D, strategic partnerships, and expansion into developing markets will be critical for companies aiming to strengthen their competitive position through 2034.

Segmentation By Disease Indication

  • Pulmonary Embolism (PE)
  • Deep Vein Thrombosis (DVT)
  • Atrial Fibrillation
  • Heart Attacks
  • Others

By Route of Administration

  • Oral
  • Injectable

By Distribution Channel

  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

By Geography

  • North America (U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
  • Latin America (Brazil, Mexico, and Rest of Latin America)
  • Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities

4. Key Insights

  • 4.1. Prevalence of Major Cardiovascular Diseases by Key Countries
  • 4.2. Overview of Novel Oral Anticoagulants (NOACs)
  • 4.3. Pipeline Analysis
  • 4.4. Key Industry Developments Such as Mergers & Acquisitions
  • 4.5. New Product Launches
  • 4.6. Regulatory Scenario in Key Countries
  • 4.7. Reimbursement Scenario by Key Countries

5. Global Anticoagulants Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Key Findings / Summary
  • 5.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 5.2.1. Pulmonary Embolism (PE)
    • 5.2.2. Deep Vein Thrombosis (DVT)
    • 5.2.3. Atrial Fibrillation
    • 5.2.4. Heart Attacks
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Injectable
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospitals Pharmacies
    • 5.4.2. Retail Pharmacies
    • 5.4.3. Online Pharmacies
    • 5.4.4. Others
  • 5.5. Market Analysis, Insights and Forecast - By Country
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Anticoagulants Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Key Findings / Summary
  • 6.2. Market Analysis - By Disease Indication
    • 6.2.1. Pulmonary Embolism (PE)
    • 6.2.2. Deep Vein Thrombosis (DVT)
    • 6.2.3. Atrial Fibrillation
    • 6.2.4. Heart Attacks
    • 6.2.5. Others
  • 6.3. Market Analysis - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Injectable
  • 6.4. Market Analysis - By Distribution Channel
    • 6.4.1. Hospitals Pharmacies
    • 6.4.2. Retail Pharmacies
    • 6.4.3. Online Pharmacies
    • 6.4.4. Others
  • 6.5. Market Analysis - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Anticoagulants Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Key Findings / Summary
  • 7.2. Market Analysis - By Disease Indication
    • 7.2.1. Pulmonary Embolism (PE)
    • 7.2.2. Deep Vein Thrombosis (DVT)
    • 7.2.3. Atrial Fibrillation
    • 7.2.4. Heart Attacks
    • 7.2.5. Others
  • 7.3. Market Analysis - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Injectable
  • 7.4. Market Analysis - By Distribution Channel
    • 7.4.1. Hospitals Pharmacies
    • 7.4.2. Retail Pharmacies
    • 7.4.3. Online Pharmacies
    • 7.4.4. Others
  • 7.5. Market Analysis - By Country
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Spain
    • 7.5.5. Italy
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Anticoagulants Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Key Findings / Summary
  • 8.2. Market Analysis - By Disease Indication
    • 8.2.1. Pulmonary Embolism (PE)
    • 8.2.2. Deep Vein Thrombosis (DVT)
    • 8.2.3. Atrial Fibrillation
    • 8.2.4. Heart Attacks
    • 8.2.5. Others
  • 8.3. Market Analysis - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Injectable
  • 8.4. Market Analysis - By Distribution Channel
    • 8.4.1. Hospitals Pharmacies
    • 8.4.2. Retail Pharmacies
    • 8.4.3. Online Pharmacies
    • 8.4.4. Others
  • 8.5. Market Analysis - By Country
    • 8.5.1. Japan
    • 8.5.2. China
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Anticoagulants Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Key Findings / Summary
  • 9.2. Market Analysis - By Disease Indication
    • 9.2.1. Pulmonary Embolism (PE)
    • 9.2.2. Deep Vein Thrombosis (DVT)
    • 9.2.3. Atrial Fibrillation
    • 9.2.4. Heart Attacks
    • 9.2.5. Others
  • 9.3. Market Analysis - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Injectable
  • 9.4. Market Analysis - By Distribution Channel
    • 9.4.1. Hospitals Pharmacies
    • 9.4.2. Retail Pharmacies
    • 9.4.3. Online Pharmacies
    • 9.4.4. Others
  • 9.5. Market Analysis - By Country
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Anticoagulants Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Key Findings / Summary
  • 10.2. Market Analysis - By Disease Indication
    • 10.2.1. Pulmonary Embolism (PE)
    • 10.2.2. Deep Vein Thrombosis (DVT)
    • 10.2.3. Atrial Fibrillation
    • 10.2.4. Heart Attacks
    • 10.2.5. Others
  • 10.3. Market Analysis - By Route of Administration
    • 10.3.1. Oral
    • 10.3.2. Injectable
  • 10.4. Market Analysis - By Distribution Channel
    • 10.4.1. Hospitals Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
    • 10.4.4. Others
  • 10.5. Market Analysis - By Country
    • 10.5.1. GCC Countries
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Key Industry Developments
  • 11.2. Global Market Share Analysis (2025)
  • 11.3. Competition Dashboard
  • 11.4. Comparative Analysis - Major Players
    • 11.4.1. Bristol-Myers Squibb Company
      • 11.4.1.1. Overview,
      • 11.4.1.2. Products & services,
      • 11.4.1.3. SWOT analysis,
      • 11.4.1.4. Recent developments,
      • 11.4.1.5. strategies,
      • 11.4.1.6. financials (based on availability)
    • 11.4.2. Pfizer Inc.
      • 11.4.2.1. Overview,
      • 11.4.2.2. Products & services,
      • 11.4.2.3. SWOT analysis,
      • 11.4.2.4. Recent developments,
      • 11.4.2.5. strategies,
      • 11.4.2.6. financials (based on availability)
    • 11.4.3. Bayer AG
      • 11.4.3.1. Overview,
      • 11.4.3.2. Products & services,
      • 11.4.3.3. SWOT analysis,
      • 11.4.3.4. Recent developments,
      • 11.4.3.5. strategies,
      • 11.4.3.6. financials (based on availability)
    • 11.4.4. Janssen Pharmaceuticals, Inc.
      • 11.4.4.1. Overview,
      • 11.4.4.2. Products & services,
      • 11.4.4.3. SWOT analysis,
      • 11.4.4.4. Recent developments,
      • 11.4.4.5. strategies,
      • 11.4.4.6. financials (based on availability)
    • 11.4.5. Eisai Co., Ltd.
      • 11.4.5.1. Overview,
      • 11.4.5.2. Products & services,
      • 11.4.5.3. SWOT analysis,
      • 11.4.5.4. Recent developments,
      • 11.4.5.5. strategies,
      • 11.4.5.6. financials (based on availability)
    • 11.4.6. Other Prominent Players
      • 11.4.6.1. Overview,
      • 11.4.6.2. Products & services,
      • 11.4.6.3. SWOT analysis,
      • 11.4.6.4. Recent developments,
      • 11.4.6.5. strategies,
      • 11.4.6.6. financials (based on availability)

12. Strategic Recommendations

List of Tables

  • Table 1: Global Anticoagulants Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 2: Global Anticoagulants Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
  • Table 3: Global Anticoagulants Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global Anticoagulants Market Revenue (US$ Mn) Forecast, by Region, 2021-2034
  • Table 5: North America Anticoagulants Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 6: North America Anticoagulants Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
  • Table 7: North America Anticoagulants Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Anticoagulants Market Revenue (US$ Mn) Forecast, By Country, 2021-2034
  • Table 9: Europe Anticoagulants Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 10: Europe Anticoagulants Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
  • Table 11: Europe Anticoagulants Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe Anticoagulants Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Anticoagulants Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 14: Asia Pacific Anticoagulants Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
  • Table 15: Asia Pacific Anticoagulants Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Anticoagulants Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Latin America Anticoagulants Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 18: Latin America Anticoagulants Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
  • Table 19: Latin America Anticoagulants Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Latin America Anticoagulants Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Anticoagulants Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 22: Middle East & Africa Anticoagulants Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
  • Table 23: Middle East & Africa Anticoagulants Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Middle East & Africa Anticoagulants Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Anticoagulants Market Revenue Breakdown (US$ Mn, %) by Region, 2025-2034
  • Figure 2: Global Anticoagulants Market Value Share (%), by Disease Indication, 2025-2034
  • Figure 3: Global Anticoagulants Market Forecast (US$ Mn), by Pulmonary Embolism (PE), 2021-2034
  • Figure 4: Global Anticoagulants Market Forecast (US$ Mn), by Deep Vein Thrombosis (DVT), 2021-2034
  • Figure 5: Global Anticoagulants Market Forecast (US$ Mn), by Atrial Fibrillation, 2021-2034
  • Figure 6: Global Anticoagulants Market Forecast (US$ Mn), by Heart Attacks, 2021-2034
  • Figure 7: Global Anticoagulants Market Forecast (US$ Mn), by Others, 2021-2034
  • Figure 8: Global Anticoagulants Market Value Share (%), by Route of Administration, 2025-2034
  • Figure 9: Global Anticoagulants Market Forecast (US$ Mn), by Oral, 2021-2034
  • Figure 10: Global Anticoagulants Market Forecast (US$ Mn), by Injectable, 2021-2034
  • Figure 11: Global Anticoagulants Market Value Share (%), by Distribution Channel, 2025-2034
  • Figure 12: Global Anticoagulants Market Forecast (US$ Mn), by Hospitals Pharmacies, 2021-2034
  • Figure 13: Global Anticoagulants Market Forecast (US$ Mn), by Retail Pharmacies, 2021-2034
  • Figure 14: Global Anticoagulants Market Forecast (US$ Mn), by Online Pharmacies, 2021-2034
  • Figure 15: Global Anticoagulants Market Forecast (US$ Mn), by Others, 2021-2034
  • Figure 16: Global Anticoagulants Market Value (US$ Mn), by Region, 2025-2034
  • Figure 17: North America Anticoagulants Market Value (US$ Mn), by Disease Indication, 2025-2034
  • Figure 18: North America Anticoagulants Market Value Share (%), by Disease Indication, 2025
  • Figure 19: North America Anticoagulants Market Value (US$ Mn), by Route of Administration, 2025-2034
  • Figure 20: North America Anticoagulants Market Value Share (%), by Route of Administration, 2025
  • Figure 21: North America Anticoagulants Market Value (US$ Mn), by Distribution Channel, 2025-2034
  • Figure 22: North America Anticoagulants Market Value Share (%), by Distribution Channel, 2025
  • Figure 23: North America Anticoagulants Market Value (US$ Mn), By Country, 2025-2034
  • Figure 24: North America Anticoagulants Market Value Share (%), By Country, 2025
  • Figure 25: Europe Anticoagulants Market Value (US$ Mn), by Disease Indication, 2025-2034
  • Figure 26: Europe Anticoagulants Market Value Share (%), by Disease Indication, 2025
  • Figure 27: Europe Anticoagulants Market Value (US$ Mn), by Route of Administration, 2025-2034
  • Figure 28: Europe Anticoagulants Market Value Share (%), by Route of Administration, 2025
  • Figure 29: Europe Anticoagulants Market Value (US$ Mn), by Distribution Channel, 2025-2034
  • Figure 30: Europe Anticoagulants Market Value Share (%), by Distribution Channel, 2025
  • Figure 31: Europe Anticoagulants Market Value (US$ Mn), By Country/ Sub-region, 2025-2034
  • Figure 32: Europe Anticoagulants Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 33: Asia Pacific Anticoagulants Market Value (US$ Mn), by Disease Indication, 2025-2034
  • Figure 34: Asia Pacific Anticoagulants Market Value Share (%), by Disease Indication, 2025
  • Figure 35: Asia Pacific Anticoagulants Market Value (US$ Mn), by Route of Administration, 2025-2034
  • Figure 36: Asia Pacific Anticoagulants Market Value Share (%), by Route of Administration, 2025
  • Figure 37: Asia Pacific Anticoagulants Market Value (US$ Mn), by Distribution Channel, 2025-2034
  • Figure 38: Asia Pacific Anticoagulants Market Value Share (%), by Distribution Channel, 2025
  • Figure 39: Asia Pacific Anticoagulants Market Value (US$ Mn), By Country/ Sub-region, 2025-2034
  • Figure 40: Asia Pacific Anticoagulants Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 41: Latin America Anticoagulants Market Value (US$ Mn), by Disease Indication, 2025-2034
  • Figure 42: Latin America Anticoagulants Market Value Share (%), by Disease Indication, 2025
  • Figure 43: Latin America Anticoagulants Market Value (US$ Mn), by Route of Administration, 2025-2034
  • Figure 44: Latin America Anticoagulants Market Value Share (%), by Route of Administration, 2025
  • Figure 45: Latin America Anticoagulants Market Value (US$ Mn), by Distribution Channel, 2025-2034
  • Figure 46: Latin America Anticoagulants Market Value Share (%), by Distribution Channel, 2025
  • Figure 47: Latin America Anticoagulants Market Value (US$ Mn), By Country/ Sub-region, 2025-2034
  • Figure 48: Latin America Anticoagulants Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 49: Middle East & Africa Anticoagulants Market Value (US$ Mn), by Disease Indication, 2025-2034
  • Figure 50: Middle East & Africa Anticoagulants Market Value Share (%), by Disease Indication, 2025
  • Figure 51: Middle East & Africa Anticoagulants Market Value (US$ Mn), by Route of Administration, 2025-2034
  • Figure 52: Middle East & Africa Anticoagulants Market Value Share (%), by Route of Administration, 2025
  • Figure 53: Middle East & Africa Anticoagulants Market Value (US$ Mn), by Distribution Channel, 2025-2034
  • Figure 54: Middle East & Africa Anticoagulants Market Value Share (%), by Distribution Channel, 2025
  • Figure 55: Middle East & Africa Anticoagulants Market Value (US$ Mn), By Country/ Sub-region, 2025-2034
  • Figure 56: Middle East & Africa Anticoagulants Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 57: Global Anticoagulants Market Share (%), By Company, 2025